Reported sales growth outpaced operating profit growth
The profit and revenue figures use different income-statement levels
Watch: Look for margin repair from Q2's 17.8%
Home / Research / Dabur India Limited
Reported sales growth outpaced operating profit growth
https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=c63f100c-5541-4df4-8d6a-cf6eee807d8b.pdf
https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=c63f100c-5541-4df4-8d6a-cf6eee807d8b.pdf
https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=c63f100c-5541-4df4-8d6a-cf6eee807d8b.pdf
https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=c63f100c-5541-4df4-8d6a-cf6eee807d8b.pdf
The profit and revenue figures use different income-statement levels
Watch: Look for margin repair from Q2's 17.8%
Higher sales were supported by varied categories and channels
Watch: Test physical volume contribution
Profit growth trailed reported revenue growth
Watch: Watch input costs and discretionary spending
Operating margin fell 60 basis points
Watch: Test whether pricing and mix recover the gap
Reporting period: 30 September 2026 quarter and H1 FY27. Basis: issuer-reported consolidated figures unless otherwise identified. Stance: WATCH. [S1][S2]
Dabur's Q2 growth was stronger at the revenue line than at the operating-profit line. Consolidated revenue from operations rose 11.6% year-on-year to ₹3,563.1 crore, operating profit grew 7.5% to ₹632.5 crore, and the operating margin slipped from 18.4% to 17.8%. Reported PAT after minority interest increased 11.7% to ₹505.5 crore. These are distinct financial layers; the issuer's ₹804.3 crore EBITDA *including other income* is not the same as ₹632.5 crore operating profit. [S2]
| Consolidated metric | Q2 FY26 | Q2 FY27 | H1 FY26 | H1 FY27 |
|---|---|---|---|---|
| Revenue (₹ crore) | 3,191.3 | 3,563.1 | 6,595.9 | 7,327.5 |
| Operating profit (₹ crore) | 588.1 | 632.5 | 1,255.9 | 1,373.8 |
| Operating profit margin | 18.4% | 17.8% | 19.0% | 18.7% |
| EBITDA including other income (₹ crore) | 728.2 | 804.3 | 1,540.0 | 1,718.3 |
| PAT after minority (₹ crore) | 452.6 | 505.5 | 966.5 | 1,096.4 |
All table values: issuer's consolidated P&L, Q2 and H1 FY27 presentation [S2]. No valuation or market price is inferred.
Six investment takeaways: Revenue growth of 11.6% is encouraging but does not offset the 60-basis-point year-on-year operating margin compression; consolidated raw-material costs increased 13.0% versus revenue growth of 11.6%. India FMCG growth was presented at 20.0%, with volume growth of 5.5%, warranting a mix/price versus throughput distinction. Home & Personal Care delivered ₹1,385 crore and 12.3% growth, while Healthcare contributed ₹623 crore and 5.5% growth, reflecting uneven category momentum. Hair oils and shampoos grew in the high teens but honey faced a mid-single-digit decline and trade-sentiment disruption. International business growth was shown at 10.7%; currency and geography affect comparable local momentum. Standalone revenue grew 8.9% to ₹2,432.9 crore and standalone operating profit 8.2% to ₹458.7 crore, so the India company and consolidated group must not be interchanged. [S1][S2]
This graphical Investment Briefing is followed by the distinct seven-chapter main report below.
Dabur offers diversified branded exposure to oral care, hair care, home care, personal care, health supplements, digestives, beverages, and foods, alongside a substantial international operation. The company has meaningful distribution reach and enduring brands, yet the current investment judgment hinges on *quality* of growth, not merely how many categories register double-digit top-line expansion. [S1][S2]
Decision: WATCH. The quarter supports stronger consumer/brand activity and higher operating profit in rupees, but operating margin decreased by 60 bps as inputs and other expenses grew faster than sales. An investor paying a premium for a defensive branded franchise would need evidence of stable or improving gross margins, volume-driven India FMCG growth and consistent after-tax cash conversion. The source packet does not establish the current share price, diluted share count, enterprise valuation or prospective free cash flow needed for a responsible numerical fair-value estimate. [S2]
Management's November 5 analyst meeting emphasized more focused brand investment, a stronger position in health and wellness, portfolio transformation and better execution quality. The CEO described these as priorities informed by discussions with consumers, customers and colleagues. These statements are management intentions, not completed projects or guarantees of a specific margin trajectory. [S1]
Key underwriting conditions
A valuation premium would demand predictable unit economics despite volatile commodity inputs; a discount would become more plausible if pricing, inflation and new-channel costs repeatedly absorb incremental revenue.
Consolidated Q2 revenue of ₹3,563.1 crore compared with ₹3,191.3 crore in Q2 FY26, an 11.6% rise. Consolidated material costs rose from ₹1,613.5 crore to ₹1,822.7 crore, or 13.0%, outpacing revenue. Employee costs rose 8.3%; advertisement/publicity expense declined 3.0%; and other expenses increased 23.6%, from ₹408.3 crore to ₹504.6 crore. These cost movements coincide with the operating-margin slide from 18.4% to 17.8%. A single quarter cannot establish permanent margin deterioration, but the direction challenges any assumption of automatic operating leverage. [S2]
The company distinguishes operating profit of ₹632.5 crore, up 7.5%, from EBITDA *including other income* of ₹804.3 crore, up 10.5%, and PAT after minority of ₹505.5 crore, up 11.7%. These metrics answer different questions. Operating profit tests brand and production economics; EBITDA including other income is broader; PAT reflects depreciation, financing, tax and noncontrolling adjustments. Investors should not choose whichever denominator produces the strongest-looking margin. [S2]
| Consolidated costs (₹ crore) | Q2 FY26 | Q2 FY27 | YoY |
|---|---|---|---|
| Material cost | 1,613.5 | 1,822.7 | +13.0% |
| Employee expense | 347.9 | 376.8 | +8.3% |
| Advertisement and publicity | 233.6 | 226.6 | −3.0% |
| Other expenses | 408.3 | 504.6 | +23.6% |
| Operating profit | 588.1 | 632.5 | +7.5% |
For H1 FY27, consolidated revenue grew 11.1% to ₹7,327.5 crore; operating profit grew 9.4% to ₹1,373.8 crore; and operating margin was 18.7% versus 19.0% in H1 FY26. H1 PAT rose 13.4% to ₹1,096.4 crore. Standalone revenue and operating profit were ₹2,432.9 crore and ₹458.7 crore for Q2, growing 8.9% and 8.2%; standalone margin was 18.9% versus 19.0%. These standalone figures should be labeled separately from the consolidated 17.8% margin. [S2]
Earnings-quality tests
The investor presentation groups a wide portfolio into Home & Personal Care, Healthcare, and Foods & Beverage. Home & Personal Care reached approximately ₹1,385 crore, with 12.3% growth; Healthcare reached approximately ₹623 crore with 5.5% growth. The mix matters: an incumbent healthcare/wellness franchise can exhibit weaker near-term demand even while hair oils, shampoos, digestives or foods register stronger momentum. Revenue scale is not the same as segment profit, and the accepted presentation does not provide equally detailed current EBIT numbers for every brand. [S2]
In oral care, toothpaste and toothpowder reportedly grew in the mid-single digits, while the herbal range performed more strongly. Hair oils and shampoos both achieved high-teens growth, with perfumed/coconut-oil strength in the former. Odonil grew double digit and new car freshener/automatic diffuser formats showed management-reported early traction; Odomos rose in the mid-single digits, and Sanifresh achieved double-digit performance. Skin care grew in the high single digits, led by the Oxy franchise. [S2]
Healthcare was uneven. Chyawanprash grew in the low single digits, but honey declined mid-single digit, partly attributed to temporary trade sentiment after an FSSAI labeling-related order. This should be treated as an issuer-described disruption, not dismissed until sell-through and shelf availability recover. Digestives performed better: Hajmola recorded double-digit growth, while Pudin Hara and Isabgol saw strong double-digit momentum. Health juices were described as maintaining high-teen growth. [S2]
Beverages reported mid-teens expansion, helped by nectar and Activ; foods continued strong double-digit growth, including Badshah. Management linked this to brand-building, consumer activations and increasing quick-commerce investment. These are plausible channels for incremental reach but should be tested against fulfillment cost, returns, discounting and repeat-purchase patterns rather than treating quick commerce as cost-free sales. [S1][S2]
Brand/channel monitoring
At the November 5, 2026 analyst/institutional meeting, management discussed Dabur's legacy reach, consumer trust, regional and channel distribution, and the opportunity to adapt its portfolio for younger, digitally engaged buyers. The India CEO, Herjit Bhalla, highlighted four themes from early stakeholder discussions: increase focused support behind brands, reinforce health-and-wellness leadership, transform the portfolio for changing needs and improve execution quality. These are leadership priorities; the test is whether they become measurable distribution, innovation and profitability improvements. [S1]
Management also identified a demanding external environment, particularly input inflation and geopolitical energy-price volatility. It described mix management, cost optimization and calibrated pricing as controllable responses. This is a credible operating framework, but does not establish that consumers will accept every price increase or that commodities will normalize quickly. The Q2 numbers show why it matters: material cost rose 13% versus 11.6% revenue growth, while other expenses accelerated even faster. [S1][S2]
The important investment questions from the presentation and investor meeting are company-specific: how quickly can an established herbal portfolio extend into science-backed wellness without diluting its core identity? What incremental sales are created by quick commerce rather than moved from traditional retail? How many newer launches reach repeat-scale profitability, and how does that affect promotion and distribution cost? How does management protect the Dabur honey reputation while addressing regulatory and trade sentiment? [S1][S2]
Execution scorecard
The transcript's qualitative consumer, customer and employee perspectives are context, not measured market research. Where no numerical milestone is disclosed, no artificial completion date is assigned.
Dabur's branded portfolio can create attractive cash economics when inventory, trade credit and marketing commitments are controlled. However the accepted Q2 presentation is predominantly a P&L and category-performance package; it does not provide a complete operating-cash-flow, net-debt, project capex or payback bridge sufficient to quantify free cash flow and returns on new investment here. It would be inappropriate to infer cash conversion simply from the ₹632.5 crore Q2 operating profit or ₹505.5 crore PAT after minority. [S2]
A working-capital assessment should distinguish materials procurement for healthcare, hair care and beverages; trade/modern-retail receivables; inventory in distributors and quick-commerce fulfillment; and seasonal promotions around the quarter. The material-cost growth of 13% and other-expense growth of 23.6% make cost discipline a live question. Both reported movements are evidence; a specific change in inventory days would need actual balance-sheet figures not established in the two documents. [S2]
The CEO's stated intention to sharpen brand spending creates a sensible trade-off. Cutting advertising can temporarily support a quarterly margin, but chronic underspending may weaken brand equity; increasing it can build demand but lower near-term profits. Q2 group A&P was ₹226.6 crore, down from ₹233.6 crore, while revenue grew strongly. Investors need to assess the next few quarters rather than mechanically praising the lower A&P number. [S1][S2]
Cash/capital tests
The absence of certain source-period balance sheet detail is a real evidence limit, not proof of a financial weakness.
Bull case — broad volume-led recovery with margin repair. India FMCG volumes improve from the 5.5% quarterly reference, hair/oil/oral categories broaden their gains, honey trade disruption normalizes, quick commerce produces incremental profitable sales, and operating profit starts growing at least as fast as revenue. With input pressure managed, consolidated operating margin recovers from Q2's 17.8% toward or above the year-earlier 18.4%. Such a case merits a higher-quality earnings assessment only after cash conversion and market valuation are checked. This is a conditional scenario, not a company or analyst earnings forecast.
Base case — revenue resilient but cost pressure remains. India FMCG and international operations continue to grow with mixed category performance; healthcare lags some personal-care and food businesses; commodity and execution costs constrain margin. H1's 18.7% operating margin versus 19.0% previously illustrates that revenue momentum and mild margin dilution can coexist. In this setting, the valuation burden is on price and cash-flow durability rather than a simple sales-growth extrapolation.
Bear case — inflation, competition or execution disrupts earnings. Higher material costs outpace pricing, healthcare demand or honey distribution remains weak, investments in quick commerce/new launches fail to earn their cost, and volume growth falls. A sustained margin step-down accompanied by weaker cash conversion would undermine the premium consumer-franchise thesis. There is no evidence to assert a particular drawdown or price target from the accepted issuer documents.
| Monitoring test | Q2 FY27 reported anchor | Positive case | Negative case |
|---|---|---|---|
| Group sales | +11.6% YoY | Broad volume-supported growth | Price-led sales with weak demand |
| Operating margin | 17.8% | Recovery toward prior 18.4% | Multi-quarter compression |
| India FMCG volume | +5.5% | Acceleration across categories | Persistent slowing |
| Home & Personal Care | ₹1,385 crore | Balanced brand growth | Narrow category dependence |
| Healthcare | ₹623 crore | Honey recovery, supplements improve | Trade-disruption persists |
| Material cost | +13.0% YoY | Inflation absorbed | Costs outgrow pricing and volumes |
No probabilistic scenario weights, equity price projections or dividend assumptions are fabricated.
Current stance: WATCH; reassess on evidence rather than narratives. A longer-horizon consumer investor should examine Dabur's earnings durability at the current price, fully diluted market capitalization, net cash/debt and verified operating cash flow. That valuation exercise is outside this Q2 issuer-only source pair and should not be reverse-engineered from sales growth alone. The seven-chapter analysis is intended to identify the key variables that must enter such a model.
Before upgrading the thesis: require evidence that growth translates into stable gross and operating margins, that healthcare/honey disruptions are resolving, and that investment in newer formats produces profitable repeat purchases. Use H1 consolidated revenue ₹7,327.5 crore, operating profit ₹1,373.8 crore and PAT ₹1,096.4 crore as the six-month bases; do not mix with standalone ₹5,120.2 crore H1 revenue. [S2]
Next-quarter scoreboard
The investment view should weaken if margins and cash generation deteriorate over multiple quarters despite healthy headline revenue; it should strengthen if volume and earnings quality improve together at a defensible market valuation.
[S1] Dabur India analyst and institutional investor meet transcript, event 5 November 2026, BSE filing 10 November 2026. [S2] Dabur India Q2 FY27 investor presentation, BSE filing 4 November 2026.
These original filings provide the source basis. Management intentions are not modeled as realized outcomes. This source-led report is not a statutory audit, peer valuation model, price-target recommendation or independent verification of future projections.
https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=c63f100c-5541-4df4-8d6a-cf6eee807d8b.pdf
https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=c63f100c-5541-4df4-8d6a-cf6eee807d8b.pdf
https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=c63f100c-5541-4df4-8d6a-cf6eee807d8b.pdf
https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=c63f100c-5541-4df4-8d6a-cf6eee807d8b.pdf
This is dated research, not a live market quote. Scenarios and historical performance are not guarantees.